Can we count your visit with Google Analytics? No ads, no profiles. Details
CANF
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: nano-cap Israeli biotech with proprietary A3 adenosine receptor platform; dual NASDAQ/TASE listing provides visibility but float is extremely thin.
CF101 NASH readout could be transformative in an underserved indication; A3AR mechanism is differentiated vs. GLP-1 wave; low base market cap means binary upside on a positive trial.
Phase II NASH data historically poor across the industry; cash runway risk for sub-$10M market-cap company; Israeli geopolitical risk premium; dilution via ATM is near-certain.
It reads our $CANF data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.